| Symbol | BLRX |
|---|---|
| Name | BIOLINE RX LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | BIOMED |
| Address | 2 HAMAAYAN STREET, MODIIN, 7177871, Israel |
| Telephone | 08-6429100 |
| Fax | 08-6429101 |
| info@biolinerx.com | |
| Website | www.biolinerx.com |
| Incorporation | Israel |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001498403 |
| Description | BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions. Additional info from NASDAQ: |
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Read moreBioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Read moreNew Form D - BioLineRx Ltd. <b>Filed:</b> 2026-09-09 <b>AccNo:</b> 0001178913-26-004469 <b>Size:</b> 15 KB
Read moreNew Form 424B5 - BioLineRx Ltd. <b>Filed:</b> 2026-08-31 <b>AccNo:</b> 0001178913-26-004339 <b>Size:</b> 645 KB
Read moreBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreBioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more